Iberdomide: A Novel Drug for Lupus: Dr. Kathryn Dao

Dr. Kathryn Dao discusses abstract OP0132, "Effect of Iberdomide on Cutaneous Manifestations in Systemic Lupus Erythematosus: Results of a 24-Week, Placebo-controlled, Phase 2 Study", presented at the EULAR 2021 meeting.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.